Intrinsic Value
BridgeBio Pharma, Inc. · BBIO
Conservative
More adverse but historically defensible assumptions.
-$2,658.78
Base
The model's central intrinsic-value estimate.
-$4,419.51
Optimistic
More favorable but historically defensible assumptions.
-$7,544.19
Scenarios are the same model run under different but historically defensible assumptions. They are not price targets. Where a valuation gap is shown it is a comparison with a recent close, not a forecast return; where the price is stale, no gap is shown at all.
Model confidence: 65%Valuation as of Sep 21, 2026Latest filing used Feb 24, 2026
Confidence reflects data completeness, accounting quality, and model reliability. It is not a probability of future price.
Valuation drivers
- Normalized operating margin
- -659.6%
- Normalized NOPAT margin
- -521.1%
- Revenue growth
- 68.8%
- WACC
- 8.23%
- Terminal growth
- 2.50%
- Reinvestment method
- capital turnover
- Terminal-value share
- 73.8%
Model notes (2)
- Terminal value is 78% of enterprise value (Optimistic case)
- Interest-bearing debt unavailable
Model details
- Normalization
- V1
- Scenario
- V2
- Confidence
- V1
- Engine version
- valuation-1.0.1-share-units-terminal
- Data snapshot
- filed:2026-02-24